UNH

UnitedHealth is a high-quality compounder that has been heavily beaten down. Long-term demand for US healthcare should remain substantial, and the insurance model can generate attractive economics at scale. Premium revenue is recurring, and scale confers real advantages in cost of care and in data.

The drawdown is the opportunity and the warning at the same time. Insurers de-rate when medical cost trend runs ahead of pricing, and that gap cannot close within a quarter because premiums are set annually in advance.

There was a short period during which I sold the position and later rebuilt it. That sequence is best described as a reassessment followed by a re-entry: I exited the holding, re-examined the situation, and re-established the position.

The variable that matters is whether the medical loss ratio stabilises. Revenue growth is not the question for an insurer of this size. Margin is. Operating margin recovering toward its historical band would confirm the thesis; continued deterioration alongside further reserve strengthening would break it.